Peptide finder

What are you trying to change?

Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive. So you can see where the evidence is before you choose.

1. 01TestosteroneHormoneModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 5,246 people given it.10 reported

   5,246 people2 studies1 found nothing

   • Testosterone did not raise the risk of heart attacks or strokes in the men most likely to have one. More than 5,000 men aged 45 to 80 took part. All had low testosterone with symptoms, and all were already at risk of heart trouble. Half rubbed on a testosterone gel and half a dummy gel. After about three years, heart...

     New England Journal of Medicine, 2023 · 5,246 people

   • found nothingTestosterone helped older men with sex and did much less for everything else. It raised their levels to what a man in his twenties or thirties would have. Sex drive, sexual activity and erections all clearly got better. Energy did not get better at all. Walking distance only improved when three studies were lumped...

     New England Journal of Medicine, 2016 · number of people not given

2. 02Testosterone cypionateHormoneModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 5,246 people given it.9 reported

   5,246 people1 study

   • The one large safety study found no extra heart attacks, strokes or heart deaths on testosterone. More than 5,000 men took part, all already at risk of heart trouble. It is here because it is the best safety proof any testosterone product has. Note what it tested. Men rubbed on a gel that doctors adjusted to a set...

     New England Journal of Medicine, 2023 · 5,246 people

3. 03TriptorelinPeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 4 completed trials, 1,388 people given it.5 reported

   1,388 people3 studies

   • Triptorelin reliably shuts testosterone down in men with advanced prostate cancer. Researchers pooled 920 men from nine studies and tracked testosterone for a year. About eight in ten were fully suppressed after one month, and about nine in ten from three months onward. This adds up nine studies. It is not one study...

     Advances in Therapy, 2017 · 920 people

   • This trial is about when to give radiotherapy, not about triptorelin, and it found no advantage in giving it early. Triptorelin was the hormone treatment handed to both groups, so it was never the thing being tested. 424 men who had had prostate surgery were assigned to immediate radiotherapy or to waiting until their...

     The Lancet Oncology, 2020 · 424 people

   • The six month injection held back puberty in children who had started it far too early. 44 children who had never been treated, 39 girls and five boys, were given the long acting form across 18 centres. By six months, 41 of them had hormone levels back in the prepubertal range, and by a year almost all did. Everybody...

     Journal of Pediatric Endocrinology and Metabolism, 2016 · 44 people

4. 04DegarelixPeptideModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 610 people given it.3 reported

   610 people1 study

   • Degarelix shut testosterone down as well as the older drug and did it far faster. 610 men with prostate cancer, typically in their early seventies, got one of two degarelix schedules or a monthly leuprolide injection. By a year, nearly all men in every group were fully suppressed. The difference showed at day three,...

     BJU International, 2008 · 610 people

5. 05LeuprolidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 199 people given it.3 reported

   199 people1 study

   • It matched the older treatment and was far easier to live with. A hundred and ninety nine men with prostate cancer that had spread took either leuprolide or the oestrogen drug used at the time. Both shut testosterone down about as well. The men on leuprolide had much less breast growth, sickness and swelling, and far...

     New England Journal of Medicine, 1984 · 199 people

6. 06DHEAHormoneModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 267 people given it.5 reported

   168 people2 studies1 found nothing

   • found nothingThe biggest study of DHEA against a dummy pill as an anti-ageing supplement found nothing that mattered. 144 older men and women with low levels took it for two years. The hormone went up and little else changed. Body shape, strength, fitness, blood sugar control and quality of life did not get better. Bone density...

     The New England Journal of Medicine, 2006 · 144 people

   • In women whose adrenal glands make no DHEA, replacing it helped mood and sexual interest. 24 women took DHEA for four months and a dummy pill for four months. It is a study of people who lack the hormone, not of ageing.

     The New England Journal of Medicine, 1999 · 24 people

7. 07GonadorelinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 110 people given it.8 reported

   110 people3 studies

   • Pulsed gonadorelin brought hormones back in nearly every man, but fertility depended on his history. 76 men missing a hormone signal wore a pump that gave a small dose every one to two hours for up to two years. Testosterone and the pituitary signal came back to normal in almost all. Men who had been through some...

     Journal of Clinical Endocrinology and Metabolism, 2002 · 76 people

   • The pump got sperm going sooner, but no more men got there in the end. 28 men producing no sperm were compared: 10 wore a gonadorelin pump and 18 took the usual hormone injections. Nobody was assigned by chance, so the groups were not built alike. First sperm appeared at about six months on the pump against fourteen...

     American Journal of Men's Health, 2019 · 28 people

   • Given the way the body gives it, in pulses from a pump, gonadorelin restarted puberty in men whose brains were not signalling. Six men with this condition wore a pump delivering small doses under the skin. Their pituitary hormones were normal within a week. Testosterone rose from 77 to 520 units over a month, into the...

     New England Journal of Medicine, 1982 · 6 people

8. 08ForskolinSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 53 people given it.5 reported

   30 people1 study

   • Body fat fell and testosterone rose, in thirty overweight men. The men all had a body mass index of 26 or above and took 250 mg of a 10 percent forskolin extract twice a day, or a dummy, decided by chance, for 12 weeks. Scans showed body fat percentage and fat mass dropped against the dummy group. Bone mass changed...

     Obesity Research, 2005 · 30 people

9. 09HCGBiologicLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 55 people given it.8 reported

   29 people1 study

   • A small shot of hCG kept the testicles working while men were on testosterone. Twenty nine healthy men had their own hormone signal switched off by testosterone, which normally shuts the testicles down. Those also given a low dose of hCG every other day held testosterone inside the testicle near normal. That is a...

     Journal of Clinical Endocrinology and Metabolism, 2005 · 29 people

10. 10Kisspeptin-10PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 4 completed trials, 44 people given it.8 reported

    11 people3 studies

    • This study used kisspeptin-54, which is a different molecule from the kisspeptin-10 people buy. It was the first time any kisspeptin was given to humans. Six men received a 90 minute drip, and the two pituitary hormones that drive the testes went up, and so did testosterone. Six men is a very small group, everybody...

      Journal of Clinical Endocrinology and Metabolism, 2005 · 6 people

    • The same dose of kisspeptin-10 does completely different things in men and women. In men, a single injection raised the hormones that drive the testes at very low doses. In women in the first half of their cycle, nothing happened, even at much higher doses given three different ways. In women close to ovulation, the...

      Journal of Clinical Endocrinology and Metabolism, 2011 · 5 people

    • Kisspeptin-10 switches on the hormone system that drives testosterone. Healthy men were given a single injection into a vein, and the pituitary hormone that tells the testes to work tripled within half an hour. A longer drip lasting most of a day raised that hormone and testosterone, and made the natural pulses come...

      Journal of Clinical Endocrinology and Metabolism, 2011 · number of people not given

11. 11CetrorelixPeptideModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 564 people given it.3 reported

    number of people not given1 study

    • In fertility treatment the newer drug did the same job with less of everything. Women having their ovaries stimulated were split by chance between cetrorelix and the older drug, buserelin. Cetrorelix stopped the early hormone surge that ruins an egg collection cycle, with a surge in only 1.6 of every hundred women....

      Human Reproduction, 2000 · number of people not given

12. 12EnclomipheneSmall moleculePreliminary. Studied in people, but no published study has had people take it. 1 human study where nobody was given it.6 reported

    number of people not given1 study

    • Enclomiphene raised testosterone without flattening sperm counts, which is the whole point of it. In a mid-sized trial it was compared with testosterone gel rubbed on the skin. Men on enclomiphene ended up with more testosterone and kept their sperm counts. Testosterone treatment itself tends to push sperm counts down.

      Fertility and Sterility, 2014 · number of people not given

13. 13FOXO4-DRIPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 74 people given it.8 reported

    number of people not given0 studies

    • In mice. A separate lab found the same effect. In old mice it cleared worn-out testosterone-making cells and raised testosterone.

      Aging, 2020 · number of people not given

14. 1417-alpha-estradiolHormoneAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 4 animal studies, no human study.4 reported

    number of people not given0 studies

    • In mice, a higher dose worked even better, but still only in males. At three times the earlier dose, male mice lived longer on average, and the longest-lived ones lived longer too. The same paper found NDGA and Protandim also helped male mice. Fish oil, a bile acid drug and metformin on its own did not help. Metformin...

      Aging Cell, 2016 · number of people not given

15. 15NDGASupplementAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 2 animal studies, no human study.4 reported

    number of people not given0 studies

    • In mice, this is the first report of the male-leaning lifespan result. NDGA, acarbose and 17-alpha-estradiol all helped males more than females.

      Aging Cell, 2014 · number of people not given

16. 16NRPTSupplementModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 176 people given it.3 reported

    number of people not given0 studies

    • found nothingIn mice. In the US government mouse testing program, mixed-breed mice fed nicotinamide riboside from 8 months old did not live longer, male or female, across three labs. In the same group, a drug called 17-alpha-estradiol made males live 19 percent longer on average. That shows the test could spot a big effect.

      Aging Cell, 2021 · number of people not given

17. 17OsteocalcinPeptidePreliminary. Studied in people, but no published study has had people take it. 2 human studies where nobody was given it.

    number of people not given0 studies

    • In mice. A new strain made without osteocalcin had normal bone amount, blood sugar, testosterone and muscle mass. What was off was the lining up of bone's mineral crystals, and the bones got weaker. The authors conclude osteocalcin does not act as a hormone.

      PLoS Genetics, 2020 · number of people not given

18. 18Urolithin BSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, none stating how many people.

    number of people not given0 studies

    • In mouse muscle cells in a dish and in mice. Urolithin B made the cells grow, through more protein building and less protein breakdown, and the androgen receptor was involved. In mice, a nonstop dose from a pump under the skin for 28 days made muscles bigger and cut wasting after nerve injury. Not a dose by mouth, and...

      Journal of Cachexia, Sarcopenia and Muscle, 2017 · number of people not given

19. 19EnobosarmSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 159 people given it.5 reported

    number of people not given0 studies
20. 20OxandroloneHormonePreliminary. Studied in people, but no published study has had people take it. 1 human study where nobody was given it.5 reported

    number of people not given0 studies
21. 21Nandrolone decanoateHormoneLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, none stating how many people.6 reported

    number of people not given0 studies
22. 22TUDCASupplementLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 54 people given it.7 reported

    number of people not given0 studies
23. 23Kisspeptin-54PeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 122 people given it.8 reported

    number of people not given0 studies
24. 24GHRP-2PeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 102 people given it.7 reported

    number of people not given0 studies